Report primary data from the CERPASS clinical trial in CSCC
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Mar 2022
- Due
- 31 Mar 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“primary data readout expected in early 2023”
What we found
Evidence strength A What the grades mean
The company failed to report primary data by the early 2023 deadline, pushing the timeline to Q3 2023, then Q4 2023, before finally reporting in December 2023 that the trial failed.
-
A Replimune Group, Inc. 10-K filed 2023-05-18
“As reported in February 2023, topline data from the CERPASS trial is expected to be announced in Q3 2023.” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2024-02-08
“As reported in December 2023, our randomized, controlled Phase-2 clinical trial of RP1 with cutaneous squamous cell carcinoma, referred to as CERPASS or the CERPASS trial, did not meet either of the two primary endpoints” ✓ confirmed on the page
Market reaction: the shares moved +0.2% against the S&P 500 over the three sessions around the disclosure (17 May 2023 to 22 May 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +183 days
- 2 versions
-
Version 1 · original · stated 30 Mar 2022
Deadline 31 Mar 2023 (“early 2023”) · wording expected
-
Version 2 · stated 9 Feb 2023
Deadline 30 Sep 2023 (“Q3 2023”) · wording expected
“Topline primary analysis data from this clinical trial is expected to be announced in Q3 2023”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- CERPASS clinical trial primary data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002667 · Corrections policy